I-Mab - IMAB STOCK NEWS

I-Mab (Nasdaq: IMAB) announced the clearance of its IND application by China's NMPA for TJ210/MOR210, allowing the initiation of a phase 1 clinical trial. This trial aims to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors. TJ210/MOR210, a monoclonal antibody targeting C5aR1, is designed to block tumor-promoting immune cells. The trial follows similar studies in the U.S. and is expected to accelerate drug development for patients who have not responded to existing therapies.

I-Mab (Nasdaq: IMAB) announced a follow-on public offering of 3,283,950 American depositary shares, priced at US$54.00 each, by certain pre-IPO shareholders. The offering includes a 30-day option for underwriters to buy an additional 492,590 ADSs. Proceeds will not benefit the company as they are being sold by existing shareholders. The offering is made via a prospectus supplement filed with the SEC on February 5, 2021. The company focuses on developing novel biologics in the immuno-oncology field, with a pipeline of over 15 drug candidates.

I-Mab (Nasdaq: IMAB) announced a proposed registered underwritten public offering by certain pre-IPO shareholders of 3,283,950 American depositary shares (ADSs), each representing 23 ordinary shares. An additional option allows underwriters to purchase 492,590 more ADSs. The company will not receive proceeds from this sale. The offering is made under an automatic shelf registration statement filed with the SEC on February 5, 2021. BofA Securities, Piper Sandler, and Cantor Fitzgerald are joint bookrunners for the offering.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, has announced significant clinical advancements for its CD73 antibody, uliledlimab (TJD5), targeting advanced solid tumors. The company has initiated a phase 1/2 study in China and completed initial assessments in the U.S., demonstrating the safety and clinical activity of uliledlimab in combination with PD-1 inhibitors. Detailed results are expected at major conferences in 2021. I-Mab aims to offer innovative therapies for patients unresponsive to existing treatments.

I-Mab (NASDAQ: IMAB) announced the dosing of the first patient in a phase 2 clinical trial of TJ107 (efineptakin alpha), a long-acting recombinant human interleukin-7, for glioblastoma multiforme patients in China. The trial aims to evaluate the drug's efficacy in boosting lymphocyte counts post-chemoradiotherapy. Previous studies indicated TJ107's potential in improving immune function without severe toxicity. GBM remains a challenging cancer with poor outcomes, making innovative therapies like TJ107 critical for patients.

I-Mab (Nasdaq: IMAB) and MorphoSys (Nasdaq: MOR) have initiated a phase 1 dose escalation study for TJ210/MOR210 in the U.S., focusing on patients with relapsed or refractory advanced solid tumors. This monoclonal antibody targets the C5a receptor, aiming to disrupt tumor-promoting myeloid cells. Preclinical studies indicate safety and anti-tumor activity. The trial will inform the safety and tolerability of TJ210/MOR210, with future combination studies planned. MorphoSys will receive a $1.5 million milestone payment from I-Mab as part of their collaboration agreement.

I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in several upcoming conferences in January 2021. Key events include the H.C. Wainwright BioConnect 2021 Conference on January 11, and the Citi and UBS Greater China Healthcare Corporate Days on January 14-15 and January 18-22, respectively. Notable management participants include founder Dr. Jingwu Zang and CEO Dr. Joan Huaqiong Shen. I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases, striving to transition into a fully integrated global biopharmaceutical entity.

I-Mab (Nasdaq: IMAB) announced on December 14, 2020, that its American Depositary Shares (ADS) will be included in the NASDAQ Biotechnology Index, effective December 21, 2020. This inclusion marks a significant milestone, highlighting the company's progress since its IPO in January 2020. I-Mab aims to enhance its capital market profile and provide value to shareholders, with a pipeline focused on immuno-oncology and autoimmune diseases. The NBI tracks biotechnology and pharmaceutical securities, allowing investors to follow market trends.

I-Mab (Nasdaq: IMAB) announced the advancement of its clinical development for the anti-CD47 monoclonal antibody, lemzoparlimab, in the US and China, achieving key milestones. The US combination trial will evaluate lemzoparlimab with Rituxan® and Keytruda® in non-Hodgkin lymphoma and advanced tumors, with results expected next year. In China, a phase 1/2a trial and a new IND application for a combination trial with azacitidine in AML/MDS have been accepted. I-Mab's partnership with AbbVie will support global development, positioning the company for significant advancements in cancer therapy.